IL5 and Increased total eosinophil count: The striking similarities between treatment with mepolizumab and the situation in IL-5-KO mice support the hypothesis that mepolizumab is particularly antagonizing reactive eosinophilia rather than blocking the maturation of the complete eosinophil compartment.